

Eric Alexander Secensky, MD, FACC Director of Vascular Intervention; Assistant Professor of Medicine

Printed as of 4/18/2024

Disclosures

Personal Commercial (20)			
Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Abbott Laboratories	Consultant Fees/Honoraria	Significant (>= \$5,000)	
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	
BD Bard	Speaker's Bureau	Modest (< \$5,000)	
BD Bard	Research/Research Grants	Significant (>= \$5,000)	
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Boston Scientific	Research/Research Grants	Significant (>= \$5,000)	
Cook	Speaker's Bureau	Significant (>= \$5,000)	
Cook	Research/Research Grants	Significant (>= \$5,000)	
CSI	Research/Research Grants	Significant (>= \$5,000)	
CSI	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Endovascular Engineering	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Inari	Consultant Fees/Honoraria	Modest (< \$5,000)	
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Laminate Medicial	Research/Research Grants	Significant (>= \$5,000)	Vascular Medicine
Medtronic	Research/Research Grants	Significant (>= \$5,000)	
Medtronic	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Philips	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Philips	Research/Research Grants	Significant (>= \$5,000)	
Venture Medical Group	Consultant Fees/Honoraria	Significant (>= \$5,000)	

Additional Personal Commercial Disclosures for Education Activities (0)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Baim Institute	Data Safety Monitoring Board	Modest (< \$5,000)	
Clinical Trial Enroller (3)		
Clinical Trial Enroller (3)		
) Trial Sponsor	Trial Funding Source	
Clinical Trial Enroller (3 Trial Name LightLab		Trial Funding Source	
Trial Name	Trial Sponsor	Trial Funding Source	

Institutional Financial Decision-Making Role (3)

No disclosures on record

Funding Source	Institutional Compensation Level
FDA	Significant (>= \$5,000)

Funding Source

NHLBI/NIH K23HL150290

University of California, San Francisco

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | *‡* Trial Name

Agreement

Certified Education Attestation | Signed on 5/5/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 5/5/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 5/5/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 4/6/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.



Significant (>= \$5,000)

Significant (>= \$5,000)